Cargando…

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

BACKGROUND: Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory multiple myeloma conducted at four sites in China....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bai-Yan, Zhao, Wan-Hong, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Bai, Ju, Xu, Yan, Wang, Xu-Geng, Zhang, Rui-Li, Wei, Li-Li, Zhuang, Qiu-Chuan, Fan, Frank, Zhang, Wang-Gang, He, Ai-Li, Liu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741775/ https://www.ncbi.nlm.nih.gov/pubmed/36496425 http://dx.doi.org/10.1186/s13256-022-03636-9

Ejemplares similares

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
por: Zhao, Wan-Hong, et al.
Publicado: (2022)

P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2
por: MI, Jian‑qing, et al.
Publicado: (2023)

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
por: Zhao, Wan-Hong, et al.
Publicado: (2018)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

P934: THE EFFECTS OF EXTRAMEDULLARY DISEASE ON OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Tao, Yi, et al.
Publicado: (2023)

Advances in the treatment of extramedullary disease in multiple myeloma
por: Li, Yating, et al.
Publicado: (2022)

Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis
por: Tian, Chen, et al.
Publicado: (2018)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

Extramedullary disease in multiple myeloma
por: Bansal, Radhika, et al.
Publicado: (2021)

Efficacy and follow‐up of humanized anti‐BCMA CAR‐T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary‐extraosseous, extramedullary‐bone related, and without extramedullary disease
por: Li, Wei, et al.
Publicado: (2022)

Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma
por: Xu, Juan, et al.
Publicado: (2021)

Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head
por: Sun, Wan-jun, et al.
Publicado: (2016)

Clinical features and prognosis of multiple myeloma and orbital extramedullary disease: Seven cases report and review of literature
por: Hu, Wan-Li, et al.
Publicado: (2022)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
por: Deng, Haobin, et al.
Publicado: (2021)

Clinical Characteristics and Prognostic Analysis of Multiple Myeloma with Extramedullary Disease: A SEER-Based Study
por: Li, Guang, et al.
Publicado: (2021)

Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor
por: Wang, Ying, et al.
Publicado: (2022)

(68)Ga-Pentixafor PET/CT May Fail to Detect Recurrent Multiple Myeloma with Extramedullary Disease
por: Pan, Qingqing, et al.
Publicado: (2023)

A prognostic model for patients with primary extramedullary multiple myeloma
por: Zhang, Limei, et al.
Publicado: (2022)

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
por: Dai, Hanren, et al.
Publicado: (2015)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021)

Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma
por: Han, Lu, et al.
Publicado: (2021)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

The Legend of ATP: From Origin of Life to Precision Medicine
por: Chu, Xin-Yi, et al.
Publicado: (2022)

Gut microbiota deficiency ameliorates multiple myeloma and myeloma-related bone disease by Th17 cells in mice models
por: Liu, Jia, et al.
Publicado: (2023)

Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission
por: Hu, Guan-hua, et al.
Publicado: (2022)

Correlation Between Uptake of (18)F-FDG During PET/CT and Ki-67 Expression in Patients Newly Diagnosed With Multiple Myeloma Having Extramedullary Involvement
por: Li, Qian, et al.
Publicado: (2019)

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia
por: Li, Xiangqun, et al.
Publicado: (2022)

FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma
por: Zhang, Weilong, et al.
Publicado: (2023)

Legend of the Sentinels: Development of Lung Resident Memory T Cells and Their Roles in Diseases
por: Qian, Youkun, et al.
Publicado: (2021)

The C-terminal LCAR of host ANP32 proteins interacts with the influenza A virus nucleoprotein to promote the replication of the viral RNA genome
por: Wang, Fangzheng, et al.
Publicado: (2022)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

Integrated Transcriptomic Analysis Reveals a Distinctive Role of YAP1 in Extramedullary Invasion and Therapeutic Sensitivity of Multiple Myeloma
por: Zheng, Bo, et al.
Publicado: (2022)

Extramedullary plasmacytoma of the cricoid cartilage progressing to multiple myeloma: A case report
por: WANG, MIN, et al.
Publicado: (2015)

MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
por: Zhang, Hexiao, et al.
Publicado: (2023)

Evaluation of hemilaminectomy use in microsurgical resection of intradural extramedullary tumors
por: GU, RUI, et al.
Publicado: (2014)

Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma
por: Zu, Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gk14cpjs13c645fqmj2c6k956f